Prof. Dr. Ulus Ali Şanlı is a seasoned internal medicine and medical oncology specialist at the Faculty of Medicine, Ege University, Department of Internal Medicine. He is known for his extensive clinical and academic work in the fields of breast cancer, hepatocellular carcinoma, molecular oncology, and personalized medicine. He has supervised numerous theses and taken part in various academic research projects supported by higher education institutions. His multidisciplinary approach to cancer treatment and significant number of national and international publications make him a well-respected name in the oncology community.
Academic Titles & Appointments
-
Professor, Ege University, Faculty of Medicine, Department of Internal Medicine (2010 – Present)
-
Associate Professor, Ege University (2004 – 2010)
-
Assistant Professor, Ege University (1999 – 2004)
Areas of Expertise
-
Medical Oncology (Internal Medicine)
-
Internal Medicine
-
Cancer Molecular Biology
-
Molecular Biology and Genetics
-
Breast Cancer Treatment
-
Hepatocellular Carcinoma
-
Personalized (Precision) Medicine
-
Clinical Oncology Research
-
Health and Life Sciences
Education
-
Subspecialty in Medical Oncology – Ege University, 1995–1999
-
Specialization in Internal Medicine – Ege University, 1989–1994
Thesis Work
-
Efficacy of Single-Agent Docetaxel in the Treatment of Anthracycline-Resistant Metastatic Breast Cancer (1999)
-
Evaluation of Renal Osteodystrophy in Patients Undergoing Hemodialysis and CAPD Treatment (1994)
Administrative Roles
-
Head of Oncology Department, Ege University (2018 – Present)
-
Director, Personalized Medicine Research and Practice Center (2020 – Present)
-
Board Member, Palliative Care Research and Practice Center (2020 – Present)
-
Board Member, Cancer Control Research and Practice Center (2019 – Present)
-
Faculty Board Member, Ege University (1999–2003)
Supervised Theses
-
Prevalence and Prognostic Significance of Androgen Receptor in Triple-Negative Breast Cancer – Elif Sıla Yelim, 2019
-
Synergistic Cytotoxic and Apoptotic Effects of Paclitaxel / (-)-Gossypol (AT-101) Combination in Breast Cancer Cell Lines – Kani Masaroğulları, 2010
Scientific Projects
-
Role of Nrf2 in Sorafenib-Resistant Hepatocellular Carcinoma Cell Lines
(2020–2022, Funded by Higher Education Institutions, Completed)
-
Cross-sectional Study: Prevalence and Prognostic Importance of Androgen Receptor in Triple-Negative Breast Cancer
(2018–2020, Funded by Higher Education Institutions, Completed)